Skip to main content

Tag: HIV Cure and Viral Diseases Center

Year 29 of the Jonathan Lax Memorial Lecture

This year brought luminary role models—from the clinic to nonprofits—whose mission is advancing an HIV cure and pushing societal change for those living with HIV/AIDS.

The 29th Jonathan Lax Award Lecture at The Wistar Institute celebrated three outstanding health justice champions who have made meaningful impacts in the fight against HIV and AIDS. Richard Jefferys, Basic Science, Vaccines and Cure Project director at the Treatment Action Group (TAG) who gave the keynote speech; Robb Reichard, who led The AIDS Fund, a nonprofit supporting the most vulnerable people living with AIDS in the Philadelphia community; and Dr. Jay Kostman, Philadelphia FIGHT chief medical officer, all started their  careers in the 80s and 90s when AIDS just emerged and fear of the disease brought prejudice and stigma. All three men were united in their unrelenting service to the needs of those living with HIV and spoke poignantly about the exact moment they committed to the fight against HIV.

Dr. Jay Kostman shared a visceral memory from his time as a resident at Temple University Hospital—it would set the trajectory of his 30-year career.

“My first experience was taking care of the son of a woman who worked in a Temple University lab. I remember walking into the room—but this was 1984—so you couldn’t just walk into the room of somebody who was thought to have HIV without your spacesuit on,” he said, describing the full body protective gear required to treat those with HIV. “Everybody was worried about what they might be exposed to. The thought of that has stayed with me for 40 years.”

“What must that have been like for this person at a time when HIV was a death sentence? There was no effective therapy. When I saw that young man and saw that nobody else would come in his room and sit with him, that was when I realized this is what I must do, because nobody should be treated like this.”

Robb Reichard was honored for his 20-years of advocacy, raising $18.5 million for HIV care. He shone the spotlight on those who supported him.

“I have always been surrounded by good people. In the early 1990s the LGBTQ+ Community Center offered a workshop addressing homophobia that I wanted to attend, but couldn’t afford, so my friend David paid that registration. The tools I learned in that workshop have been invaluable to me over the past 35 years.”

He went on to salute friends at all stages of his career, from a past executive director and board members to many hardworking and committed coworkers and volunteers who stood side-by-side with him during his tenure.

“I was surrounded by some incredible coworkers who worked far too hard for far too little. I could tell you so many stories about their commitment. For 12 years our offices occupied a space that had neither central heat nor central air. In the winter it was not unusual to find a coworker sitting at their computer in a winter coat and fingerless gloves so they could type. Of course, none of this work could have been done without the literally 1000s of volunteers who gave their time and energy over the years, and so many of you are here tonight. I’m not going to be able to mention you all but thank you so much.”

In his keynote speech Richard Jefferys said he got started in advocacy like many—after his friend was diagnosed.  “I wanted to find information and got connected to an organization called the AIDS Treatment Data Network, founded by an incredible woman named Eleanor Mitchell.”

Via mail he received a directory of every state’s ADA—AIDS Direct Assistance Program—for uninsured and underinsured people.

“The Administration was going to stop making this directory and we felt we should create a resource to inform people. We called every state to create a database of treatments, Medicaid programs, prior authorization requirements and created a website as soon as that was possible and we issued our first report in September 1995. The findings were appalling in that Georgia had four drugs available for people, whereas New York had scores. There were disparities all around the country. We realized quickly that with new treatments coming, these programs are going to be essential and need more funding.”

Each year the Lax Lecture is a powerful symbol and reminder to all that their dedication and shared mission to discover scientific answers, provide services, raise awareness, and fight for funding & support for HIV is bigger than the sum of its parts. This year’s Lax Lecture brought together a powerful trio sharing personal histories to emphasize the importance of community engagement and scientific collaboration in HIV research. Thirty years ago was the height of the AIDS pandemic, but thanks to the efforts and commitment of this community, we’ve progressed to the height of scientific inquiry and discovery, with sights set on an HIV cure.

Side Bar:
For the past 29 years the Jonathan Lax Memorial Lecture highlights pioneers advancing the field of HIV research with an annual lecture spotlighting cornerstone research studies and exciting new science poised to dramatically change the HIV status quo. The Lax Lecture’s success is due to the community’s role and long-term support of science and to donor support that is accelerating the changing course of HIV.

Donor Ken Nimblett has the vision and foresight to understand that today’s research will lead to tomorrow’s cure. He’s attended numerous Lax Lectures and funded Wistar HIV research over the decades. Together with his late husband Rusty Miller and Rusty’s late mother Martha Stengel Miller, the Summerhill Trust was established in part to fund cutting-edge HIV research.

This year was extra special to Ken because a panel from the AIDS Memorial Quilt was on display at Wistar during the Lax Lecture. Dr. Luis Montaner, Wistar EVP and director of the HIV Cure and Viral Diseases Center, and Mr. Reichard located the panel in a Los Angeles archive and had it delivered to Wistar. More than 50,000 panels form the AIDS Memorial Quilt, which features more than 110,000 names. Ken and his mother created a panel for Dave Giuliana, his partner, who died in 1988. 

“It is incredibly moving to see Ken and his mother’s loving contribution—a tribute created at a time when so many young lives were lost to AIDS before therapies were available,” said Dr. Montaner. “I am honored that we are able to celebrate Dave’s life and legacy at Wistar, in the presence of the scientist teams working toward a cure. The quilt’s presence—and especially Ken and Dave’s story—will be a powerful reminder and inspiration of why this pursuit must go on.”

Ken and Dave made the trip in 1987 to Washington D.C. to see the AIDS Memorial Quilt on display for the first time on the National Mall. This coincided with a National March on Washington for Lesbian and Gay Rights.  The Quilt has been displayed in its entirety five times at the National Mall with 1996 being the last time it was exhibited in its totality of 41,000 panels. Today, there are still volunteer opportunities to make a panel or repair the Quilt and ensure its legacy lives on.  

“I have a number of photos of the AIDS Memorial Quilt in 1987 on the Mall in D.C. that Dave and I went to see and experience,” says Ken. “It was an emotionally difficult experience as we knew some of the people who had been memorialized with a panel showing something of their lives as each one was such a very personal expression of who they were. Dave and I also knew that one day he would likely be gone and I would be left to make a panel for him, which I did.”

View a photo gallery of the event here.

The Wistar Institute Announces the Appointment of Qingsheng Li, Ph.D., to HIV Cure and Viral Diseases Center

PRESS RELEASE

PHILADELPHIA — (JUNE 30, 2025) — The Wistar Institute, a world leader in cancer, immunology, and infectious disease research, announces the appointment of Qingsheng Li, Ph.D., as professor in the HIV Cure and Viral Diseases Center. Li analyzes the complex immune response to HIV pathogenesis and studies HIV transmission to better understand virus – host interaction. He’s interested in one of the biggest challenges to the field: HIV virus latency (when the virus is dormant in a cell), why it reactivates and how it infects surrounding tissue. He uses genome engineering tools like CRISPR as well as RNA technologies to advance new immunotherapies.

“We are excited to welcome Qingsheng as he has been an active collaborator with Wistar for more than 15 years, including as a founding member of the BEAT-HIV Delaney Collaboratory (one of two HIV cure research consortiums in Philadelphia and one of 10 across the nation). He brings a depth of expertise in how best to measure the persistence of viral infections within tissues, which is the perfect complement to the research strategies our Wistar scientists are making alongside the HIV community,” said Luis Montaner, D.V.M., D.Phil., executive vice president, director of the HIV Cure and Viral Diseases Center and the Herbert Kean, M. D., Family Professor, at The Wistar Institute. “I can’t wait to see the collaborations he makes with our scientists who study different diseases and immunotherapy delivery systems and how the insights he gains from working with our DNA technology founder Dr. David Weiner or collaborating with Dr. Paul Lieberman through his work in Epstein-Barr virus will challenge and inspire Qingsheng to push HIV cure research to the next level.”

Li developed a way to quantify latently infected HIV virus in tissue and uses this method to detect the lowest amount of HIV DNA or RNA in patients living with HIV. This ability to quantify viral amounts helps him understand where HIV is integrated into the human chromosome. He combines this very active area of research with genome editing, using CRISPR-Cas12a technology, like molecular scissors to cut the HIV virus from the chromosome. The goal is to eventually create an immunotherapy to cure HIV.

“Wistar is known across the nation and globe as a highly regarded, top-tier research institute that has made several fundamentally important health discoveries in the 20th century—those being rabies, rubella and rotavirus. Dr. Montaner is a leader in the HIV cure field, and I couldn’t be more excited to join Wistar’s strong, established program in this exciting moment of expansion and critical mass.”

Li earned his medical degree at Datong Medical College, China, and his M.S. at Shanxi Medical University, China, and his Ph.D. at Beijing University Medical School, China. Before joining Wistar, he was a professor in the School of Biological Sciences at the University of Nebraska-Lincoln.

For a printer-friendly version of this release, please click here.

ABOUT THE WISTAR INSTITUTE:

The Wistar Institute is the nation’s first independent nonprofit institution devoted exclusively to foundational biomedical research and training. Since 1972, the Institute has held National Cancer Institute (NCI)-designated Cancer Center status. Through a culture and commitment to biomedical collaboration and innovation, Wistar science leads to breakthrough early-stage discoveries and life science sector start-ups. Wistar scientists are dedicated to solving some of the world’s most challenging problems in the field of cancer and immunology, advancing human health through early-stage discovery and training the next generation of biomedical researchers. wistar.org


Continue reading

The Wistar Institute Announces Recruitment of First Caspar Wistar Fellow to Join HIV Cure and Viral Diseases Center

PRESS RELEASE

PHILADELPHIA — (February 28, 2025) —The Wistar Institute welcomes its newest faculty member, Colby Maldini, Ph.D., who joins Wistar’s HIV Cure and Viral Diseases Center as a Caspar Wistar Fellow.

Dr. Maldini comes to Wistar with expertise in applying genome engineering technologies to develop chimeric antigen receptor T cells, more commonly known as CAR T cells: immune cells that scientists engineer to express certain proteins so that they can target specific threats, like cancer and viruses. As a member of the Caspar Wistar Fellows Program, which places young researchers on the fast track for faculty promotion, Dr. Maldini will receive support from the Institute to expand his laboratory and work toward building a mature research program.

“The HIV Cure and Viral Diseases Center is very pleased to welcome Dr. Maldini as our first external faculty recruit, which marks the beginning of an exciting expansion of an ambitious research program to seek a cure for HIV and other viral challenges,” said Luis Montaner, D.V.M., D.Phil., Wistar executive vice president, director of the HIV Cure and Viral Diseases Center, and Herbert Kean, M.D., Family Professor. “The Caspar Wistar Fellows Program has an outstanding track record of helping promising young researchers establish successful laboratories, and it is our pleasure to extend this opportunity to Dr. Maldini.”

At Wistar’s newly established Maldini lab, Dr. Maldini will continue and expand his work on CAR T cells’ role in cure approaches for HIV and other yet-to-be-cured viral infections. With backgrounds in both academic research and industrial research & development, Dr. Maldini offers Wistar his keen eye for engineering potential therapies for eventual use in clinical applications.

“The Wistar Institute has a well-deserved reputation of research excellence, so naturally, I consider it a great opportunity to join the ranks of such esteemed faculty,” said Dr. Maldini. “I look forward to the chance to work with and learn from Wistar’s countless experts. With the resources of Wistar’s famed culture of collaboration and the support of the Caspar Wistar Fellows Program, I’m excited about what we will achieve together.”

For a printer-friendly version of this release, please click here.

ABOUT THE WISTAR INSTITUTE:

The Wistar Institute is the nation’s first independent nonprofit institution devoted exclusively to foundational biomedical research and training. Since 1972, the Institute has held National Cancer Institute (NCI)-designated Cancer Center status. Through a culture and commitment to biomedical collaboration and innovation, Wistar science leads to breakthrough early-stage discoveries and life science sector start-ups. Wistar scientists are dedicated to solving some of the world’s most challenging problems in the field of cancer and immunology, advancing human health through early-stage discovery and training the next generation of biomedical researchers. wistar.org


Continue reading

The Wistar Institute Launches HIV Cure and Viral Diseases Center

PRESS RELEASE
Center Headquartered at New Wistar Market Street Campus

PHILADELPHIA — (July 16, 2024) —The Wistar Institute — building on its history of leading advances in human health as the nation’s first nonprofit biomedical research institute — is creating a new HIV Cure and Viral Diseases Center, made possible by a $24 million institutional investment from Wistar. The HIV Cure and Viral Diseases Center will advance Wistar’s dedication to cure research to meet the challenge of HIV. The goal is to move beyond current life-long treatments to eradicate the virus. The Center marshals outstanding scientific talent, research expertise, and community support to bring together the very best in foundational bench to bedside biomedical research to discover a cure for HIV and a host of viral threats.

HIV’s capacity to mutate and evade immune responses has been a challenge to scientists, and the same challenge exists for many other viruses. In pursuing a mission to find an HIV cure, key insights to overcoming other persistent viral infections will emerge, which could lead to further cures as investments in HIV research have advanced other areas of research such as the Hepatitis C cure strategy.

When announcing the Center to an audience at the Jonathan Lax Memorial Lecture, Wistar president and CEO, Dario Altieri, M.D., spoke of the historic opportunity the HIV Cure and Viral Diseases Center presents for biomedical research: “Wistar has always prioritized innovation and has provided leadership to advance solutions for the most pressing health priorities; this new Center, in combination with efforts already underway in our Vaccine & Immunotherapy Center, positions Wistar with a unique opportunity to accelerate innovative ideas for an HIV cure.”

An estimated 1.2 million Americans live with HIV, and without a cure, they must depend on life-long medications. Thanks to researchers at Wistar and across the nation and increased priority by funders to advance a cure, scientific efforts are moving ever closer to success; new technologies and strategies continue being refined and tested; and clinical trials move forward.

The HIV Cure and Viral Diseases Center will capitalize on this significant momentum for cure-directed research with a robust investment to not only discover cure strategies but prioritize those with potential for deployment. In addition to current principal investigators already working on viral cures at Wistar, four to six additional principal investigators will be recruited to the new Center. Combining expertise in virology & immunology and together with industry and community partners, the Center will follow three concurrent aims:

  • integrate multi-pronged clinical, virus-fighting methods that mimic and enhance the natural strengths of the human immune system;
  • advance successes in personalized medicine to create tailored cure strategies for individual patients and patient groups;
  • expand collaborations and capacity building to ensure cure-directed efforts include researchers and persons living with HIV.

Wistar’s HIV Cure and Viral Diseases Center is a historic, and timely undertaking also expanding Wistar beyond its signature campus at 3601 Spruce Street for the first time in its 130+year history. The Center will be headquartered at a new Wistar Market Street campus with more than 25,000 square feet dedicated to laboratory and office space.

Building upon the tremendous successes of Wistar’s HIV Research Program to launch the Center, Wistar’s Luis Montaner, D.V.M., D.Phil. — Herbert Kean, M.D., Family Professor and co-principal investigator of the BEAT-HIV Delaney Collaboratory — will lead the HIV Cure and Viral Diseases Center as founding director and newly appointed executive vice president of The Wistar Institute. As one of the Institute’s longest-serving faculty members and an established leader in the field of HIV cure research, Dr. Montaner brings decades of expertise to his leadership of the Center.

“I am confident we will advance towards an HIV cure in my lifetime, and I am honored to have the privilege of leading this bold expansion of The Wistar Institute,” said Dr. Montaner. “The HIV Cure and Viral Diseases Center builds on Wistar’s history of strength in virology, our collaborative networks, and our partnerships with industry and communities of persons living with HIV. With the launch of this Center, Wistar makes a clear and bold statement that the time to get us to an HIV cure is now.”

For a printer-friendly version of this release, please click here.

ABOUT THE WISTAR INSTITUTE:

The Wistar Institute is the nation’s first independent nonprofit institution devoted exclusively to foundational biomedical research and training. Since 1972, the Institute has held National Cancer Institute (NCI)-designated Cancer Center status. Through a culture and commitment to biomedical collaboration and innovation, Wistar science leads to breakthrough early-stage discoveries and life science sector start-ups. Wistar scientists are dedicated to solving some of the world’s most challenging problems in the field of cancer and immunology, advancing human health through early-stage discovery and training the next generation of biomedical researchers. wistar.org


Continue reading